Category: 98138-75-1

On May 14, 2015, Hatcher, John M.; Zhang, Jinwei; Choi, Hwan Geun; Ito, Genta; Alessi, Dario R.; Gray, Nathanael S. published an article.Synthetic Route of 98138-75-1 The title of the article was Discovery of a Pyrrolopyrimidine (JH-II-127), a Highly Potent, Selective, and Brain Penetrant LRRK2 Inhibitor. And the article contained the following:

Activating mutations in leucine-rich repeat kinase 2 (LRRK2) are present in a subset of Parkinson’s disease (PD) patients and may represent an attractive therapeutic target. Here the authors report JH-II-127 I, as a potent and selective inhibitor of both wild-type and G2019S mutant LRRK2. Compound I substantially inhibits Ser910 and Ser935 phosphorylation of both wild-type LRRK2 and G2019S mutant at a concentration of 0.1-0.3 μM in a variety of cell types and is capable of inhibiting Ser935 phosphorylation in mouse brain following oral delivery of doses as low as 30 mg/kg. The experimental process involved the reaction of 6-Chloro-4-methoxy-1H-pyrazolo[3,4-d]pyrimidine(cas: 98138-75-1).Synthetic Route of 98138-75-1

The Article related to pyrrolopyrimidine brain penetrant lrrk inhibitor, lrrk2, parkinson’s disease, leucine-rich repeat kinase 2, pharmacokinetics, Pharmacology: Structure-Activity and other aspects.Synthetic Route of 98138-75-1

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

Robins, Roland K. published an article in 1957, the title of the article was Potential purine antagonists. IX. Further studies of some 4,6-disubstituted-pyrazolo[3,4-d]pyrimidines.Application In Synthesis of 6-Chloro-4-methoxy-1H-pyrazolo[3,4-d]pyrimidine And the article contains the following content:

[The 4,6-disubstituted-pyrazolo[3,4-d]pyrimidines are represented in this abstract by Z, followed in parentheses by the 4- and the 6-substituent, resp.] Powd. Z(HO,HO) (I) (200 g.), 1300 cc. POCl3, and 500 cc. PhNEt2 refluxed 2 hrs., about 900 cc. excess POCl3 removed in vacuo on the steam bath, the sirupy residue poured with stirring onto crushed ice and H2O and extracted with Et2O, the extract evaporated, the residue (128 g.) extracted 5 hrs. in a Soxhlet apparatus with 250 cc. dry C6H6 and 250 cc. cyclohexane, the extract concentrated to 200 cc., and poured slowly with stirring into 1 l. petr. ether, and the precipitate recrystallized from C6H6-heptane yielded 105 g. Z(Cl, Cl) (II), m. 145° (decomposition). II (40 g.) added during 15 min. in portions to 400 cc. boiling 2N KOH with stirring, the mixture boiled with C, stirred 15 min., filtered, acidified with AcOH, cooled to 30°, and filtered, and the filtrate refrigerated 48 hrs. yielded 24.1 g. Z(HO, Cl) (III), m. above 300°; also obtained in 60% yield by refluxing the Z(MeS, Cl) (IV) with N NaOH. Z(HS, HO) (135 g.) stirred 1 hr. with 100 g. KOH and 3 l. H2O, treated with 115 cc. MeI, stirred 45 min., warmed to 50°, neutralized with AcOH, and filtered gave 120 g. Z(MeS, HO) (V). V (108 g.), 1200 cc. POCl3, and 100cc. PhNMe2 refluxed 1 hr. and worked up in the usual manner yielded 49.5 g. IV, m. 200-1° (decomposition) (PhMe) II (4.0 g.) added at 0° to 5.0 g. KOH, 100 cc. MeOH, and 20 cc. MeSH, the mixture kept 15 min. at 0°, diluted with 50 cc. ice H2O, acidified immediately with AcOH, and filtered gave 3.5 g. IV. Z(HS, Cl) (VI) (5.0 g.) added at 10° to 4.4 g. NaOH in 100 cc. H2O, shaken 10 min. with 6 g. MeI, stirred with C, filtered, acidified with AcOH, and filtered yielded 3.6 g. crude IV. Powd. II (5.0 g.) added at 0° to 200 cc. 0.5N NaOH previously saturated with H2S, stirred 15 min. at 0°, warmed to 10°, treated with C, filtered, acidified with AcOH, and filtered yielded 4.9 g. VI. II (5.0 g.) heated 20 min. on the steam bath with 75 cc. 25% aqueous MeNH2 and filtered hot gave 3.9 g. Z(MeNH, Cl) (VII), m. above 300°, also obtained in 85% yield from IV and aqueous MeNH2. Z(MeO, Cl) (VIII) and aqueous MeNH2 gave 80% VII. II (6.0 g.) added in small portions to 5.0 g. Na in 150 cc. absolute MeOH, warmed, filtered, and evaporated in vacuo, and the residue diluted with 100 cc. H2O, acidified with AcOH, cooled overnight, and filtered gave 4.8 g. VIII, m. 181-2° (C6H6). II (5 g.) and EtONa in EtOH gave similarly Z(EtO, Cl), m. 212-14° (C6H6). IV (2.0 g.) heated 0.5 hr. on the steam bath with 5 g. KOH, 10 cc. MeSH, and 100 cc. H2O, acidified with AcOH, and filtered gave 1.1 g. Z(MeS, MeS) (IX), m. 197-8° (PhMe). II (5.0 g.), 10 g. KOH, 100 cc. H2O, and 15 cc. MeSH heated 4 hrs. on the steam bath, acidified with AcOH, and filtered gave IX. II (5.0 g.) and NaOMe in MeOH refluxed 36 hrs. on the steam bath, concentrated to 50 cc., diluted with 100 cc. H2O, acidified with AcOH, and cooled yielded 3.2 g. Z(MeO, MeO), m. 222-3° (C6H6-EtOH). III (10 g.) and 100 cc. alc. NH3 heated 12 hrs. in a bomb at 200°, cooled, and filtered, the residue dissolved in 300 cc. boiling H2O with concentrated HCl, and the solution adjusted with NH4OH to pH 9 and filtered hot gave 7.6 g. Z(HO, H2N) (X). X (6 g.), 25 g. P2S5, and 300 cc. pyridine refluxed 3 hrs., cooled, and filtered, the residue added to 500 cc. H2O, heated on the steam bath overnight, treated with 50 cc. concentrated NH4OH, heated on the steam bath, cooled, and filtered, and the residue added to 700 cc. boiling H2O, dissolved with concentrated NH4OH, boiled with C, filtered hot, and reprecipitated with AcOH gave 4.1 g. Z(HS, H2N), light green needles, m. above 300°. III (2 g.) and 4.0 g. CS(NH2)2 heated 4 hrs. with 100 cc. absolute EtOH, cooled, and filtered gave Z(HO, HS). Powd. II (5 g.) carefully added to 150 cc. 20-40% aqueous primary amine, heated 10-30 min. on the steam bath, cooled, and filtered gave the corresponding 4-substituted-amino-6-chloropyrazolo[3,4-d]pyrimidine (XI) (method A). The appropriate amine (10-15 g.) in absolute EtOH treated with 5.0 g. II, heated 15-30 min. on the steam bath, cooled, and filtered gave the corresponding XI (method B). By these methods were prepared the following XI (substituent, method of preparation, and % yield given): Me (XII), A, 84; iso-Pr, A, 92; Et, A, 80; Pr, A, 95; iso-Bu, A, 83; PhCH2 (XIII), B, 78; CH2CH2OH, A, 60; cyclohexyl, B, 73; 1-C10H7, B, 70. II (1 g.) and 150 cc. 30% aqueous MeNH2 heated 12 hrs. on the steam bath, treated with more MeNH2, heated again 12 hrs., and cooled overnight gave 0.7 g. Z(MeNH, MeNH) (XIV), m. 248-50° (H2O). Similarly were prepared the following Z(RNH, RNH) (XV) (R, % yield, and m.p. given): Me, 78, 249-50° (EtOH); Et, 85, 238-40° (aqueous EtOH); Bu, 73, 182-3° (aqueous EtOH); Pr, 62, 194-5° (aqueous EtOH); CH2CH2OH, 56, 214-15° (H2O). III (2 g.) and 150 cc. 40% aqueous MeNH2 heated 8 hrs. on the steam bath, treated with an addnl. 100 cc. 40% aqueous MeNH2, and heated again 8 hrs., this treatment repeated once more, and the mixture cooled and filtered gave 62% Z(HO, MeNH). Similarly were prepared the following Z(HO, NRR’)(R, R’, and % yield given): H, Pr, 76 (aqueous EtOH); H, NH2 (hemihydrate), 70 (aqueous EtOH); Me, Me, 67 (aqueous HCONMe2); H, Me2N(CH2)3(di-HCl salt), 86 (EtOH). XIII (2.0 g.) and 100 cc. 30% aqueous Me2NH heated 8 hrs. on the steam bath, treated with 100 cc. aqueous Me2NH, heated 16 hrs., cooled, and filtered gave 1.5 g. Z(PhCH2NH, Me2N), m. 255-6° (EtOH). II (12.0 g.) and 100 cc. absolute alc. NH3 heated 12 hrs. at 100° in a bomb, cooled, and filtered, the residue washed with H2O, suspended in 800 cc. boiling H2O, dissolved by the addition of KOH, boiled 10 min. with C, and filtered hot, and the filtrate acidified with AcOH and filtered yielded 6.4 g. Z(H2N, Cl) (XVI), decompose gradually above 250°. XII (3 g.) and 150 cc. 20% aqueous Me2NH heated 8 hrs. on the steam bath, treated with an addnl. 100 cc. aqueous Me2NH, heated again 8 hrs., filtered, and cooled yielded 1.9 g. Z(MeNH, Me2N) (XVII), m. 272-3° (aqueous EtOH). VIII (2 g.) and alc. NH3 heated 8 hrs. at 100° in a bomb gave 1.1 g. XVI, also obtained under similar conditions from IV. II (5.0 g.), 10 g. CS(NH2)2, and 150 cc. EtOH refluxed 3 hrs. on the steam bath, cooled, and filtered gave 4.1 g. Z(HS, HS) (XVIII). VI (2 g.) and 100 ml. aqueous Me2NH heated 6 hrs. on the H2O bath gave 1.8 g. crude Z(HS, Me2N) (XVIII). Z(HO, Me2N) (3 g.) and 15 g. P2S5 refluxed 6 hrs. with 500 cc. pyridine, and evaporated in vacuo on the steam bath, the residue warmed with 300 cc. H2O on the steam bath, cooled, and filtered, and the residue reprecipitated from hot dilute base with AcOH yielded 0.8 g. XVIII. IV (3 g.) and 100 cc. concentrated NH4OH heated 8 hrs. at 100° in a bomb, cooled, and filtered gave 2.5 g. (crude) Z(H2N, MeS) (XIX), m. 297-8° (EtOH). Z(Cl, MeS) (3 g.), m. 178-9° (decomposition), and 100 cc. concentrated NH4OH yielded similarly 2.6 g. XIX. XIX (1 g.) in 250 cc. boiling H2O and 3 cc. HCl treated with 3 g. NaNO2, heated 10 min. on the steam bath, cooled, and filtered gave 0.4 g. Z(HO, MeS). XIX (1.5 g.), 100 cc. H2O, 10 cc. concentrated HCl, and 10 cc. 30% H2O2 boiled 20 min., neutralized with concentrated NH4OH, and filtered yielded 0.8 g. Z(H2N, HO), Rf 0.036 (PrOHNH4OH), 0.50 (concentrated HCl-iso-PrOH-H2O). VIII (2 g. and 100 cc. 30% aqueous MeNH2 heated 4 hrs. on the steam bath, cooled, and filtered yielded 1.2 g. Z(MeNH, MeS) (XX), m. 253-4° (aqueous EtOH). IX (1.5 g.) and 100 cc. 30% aqueous MeNH2 heated 4 hrs. on the steam bath gave similarly 0.9 g. XX, m. 254-5° (aqueous EtOH). Z(Cl, MeS) (3 g.) and 150 cc. 30% aqueous MeNH2 gave 1.7 g. XX. Z(MeO, MeS) (2 g.) and 130 cc. 30% aqueous Me2NH heated 1 hr. on the steam bath, cooled, and filtered yielded 1.1 g. Z(Me2N, MeS) (XXI), m. 262-5° (aqueous EtOH). IX (1.5 g.) and 100 cc. 30% aqueous Me2NH heated 3 hrs. on the steam bath gave 0.8 g. XXI. II (3 g.), 3 g. NaOH, and 15 cc. EtSH in 100 cc. EtOH kept 0.5 hr. at room temperature, acidified with AcOH, and filtered gave 1.6 g. Z(EtS, Cl), m. 149-50° (C6H6-heptane). Z(HS, H2N) (1 g.) in 30 cc. H2O containing 2.0 g. NaOH stirred 20 min. with 0.5 cc. Me2SO4, acidified with AcOH, and stored gave 0.8 g. Z(MeS, H2N), m. 240-1° (H2O). II (6 g.) and 50 cc. absolute alc. NH3 heated 24 hrs. at 200° in a bomb, the solution evaporated to dryness on the steam bath, the residue dissolved with 5 g. NaOH and 100 cc. H2O, and the solution boiled with C, neutralized with AcOH, filtered, and kept gave Z(H2N, H2N), also obtained similarly from IV or Z(Cl, MeS). The ultraviolet absorption maximum of the various XI and XV are listed. The experimental process involved the reaction of 6-Chloro-4-methoxy-1H-pyrazolo[3,4-d]pyrimidine(cas: 98138-75-1).Application In Synthesis of 6-Chloro-4-methoxy-1H-pyrazolo[3,4-d]pyrimidine

6-Chloro-4-methoxy-1H-pyrazolo[3,4-d]pyrimidine(cas:98138-75-1) belongs to pyrazoles-derivatives. The use of pyrazole derivatives is based on their analgesic, anti-inflammatory, antipyretic, antiarrhythmic, sedative, muscle relaxant, neuroleptic, anticonvulsant, monoamine oxidase inhibitory, antidiabetic and antibacterial activities.Application In Synthesis of 6-Chloro-4-methoxy-1H-pyrazolo[3,4-d]pyrimidine

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

Seela, Frank; Menkhoff, Sabine published an article in 1986, the title of the article was 2′-Deoxyribofuranosides of 6-oxoallopurinol and of related 4,6-disubstituted pyrazolo[3,4-d]pyrimidines.Computed Properties of 98138-75-1 And the article contains the following content:

Deoxypentofuranosylpyrazolopyrimidine I (R = OMe) was aminated to I (R = NH2) and demethylated to pyrimidinones II and III. I (R = OMe) was prepared by phase-transfer glycosidation of methoxylated or chlorinated pyrimidine base. The experimental process involved the reaction of 6-Chloro-4-methoxy-1H-pyrazolo[3,4-d]pyrimidine(cas: 98138-75-1).Computed Properties of 98138-75-1

The Article related to pentofuranosylpyrazolopyrimidinedione, pyrazolopyrimidine deoxypentofuranosyl glycosidation, methoxypyrazolopyrimidinylpentofuranose preparation hydrolysis, Carbohydrates: Nucleosides and Nucleotides, Cobalamins, Riboflavin and other aspects.Computed Properties of 98138-75-1

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On August 18, 2016, Gray, Nathanael S.; Hatcher, John; Choi, Hwan Geun published a patent.Name: 6-Chloro-4-methoxy-1H-pyrazolo[3,4-d]pyrimidine The title of the patent was LRRK2 inhibitors and methods of making and using the same. And the patent contained the following:

The invention relates to compounds of formula I, II, and III as LRRK2 inhibitors; their preparation and use in the treatment of neurodegenerative diseases, such as Parkinson’s disease. Compounds of formula I wherein Rx is NRARB, substituted piperidinylmethanone, substituted morpholinomethanone, etc.; RA and RB are independently (un)substituted C1-6 alkyl and COR7; R7 is (un)substituted C1-6 alkyl, (un)substituted C2-6 alkenyl, (un)substituted C2-6 alkynyl; X1, X2 and X3 are independently N, NH and derivatives, substituted C; Rn is H and (un)substituted C1-6 alkyl; each R1 is independently (un)substituted C1-6 alkyl, (un)substituted C1-6 alkoxy and halo; m = 0 – 3; R2 is H, alkoxy, halo, etc.; and pharmaceutically acceptable salts thereof, are claimed. Example compound IV was prepared by a multistep procedure (procedure given). The invention compounds were evaluated for their LRRK2 inhibitory activity (some data given). The experimental process involved the reaction of 6-Chloro-4-methoxy-1H-pyrazolo[3,4-d]pyrimidine(cas: 98138-75-1).Name: 6-Chloro-4-methoxy-1H-pyrazolo[3,4-d]pyrimidine

The Article related to pyrrolopyrimidine preparation lrrk2 inhibitor treatment neurodegenerative disease, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Name: 6-Chloro-4-methoxy-1H-pyrazolo[3,4-d]pyrimidine

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On June 25, 2020, Brenneman, Jehrod Burnett; Krall, Elsa Beyer; Schlabach, Michael; Wylie, Andrew Alistair published a patent.Recommanded Product: 6-Chloro-4-methoxy-1H-pyrazolo[3,4-d]pyrimidine The title of the patent was Preparation of substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors. And the patent contained the following:

The present disclosure provides compounds having formula I and the pharmaceutically acceptable salts and solvates thereof, wherein X1, X2 is independently N and CR2; R1 and R2 are independently H, halo, cyano, (un)substituted alkyl, etc.; R3 is (un)substituted Ph, pyridinyl, pyrazolyl, etc.; X11 and X12 is independently N and CH; R5′ is H, (un)substituted C1-6alkyl, (un)substituted C1-6alkoxy, etc.; R5 is (un)substituted C1-6alkyl, (un)substituted C2-6alkenyl, C1-6haloalkyl, etc.; R6 and R7 is independently H, halo, CN, (un)substituted alkenyl, etc. The present disclosure is also directed to the use of compounds of Formula I to inhibit a USP1 protein and to treat a disorder responsive to the inhibition of USP1 proteins and USP1 activity. Example compound II was prepared via a multistep procedure (procedure given). From the assay, it was determined that example compound II exhibited IC50 value of > 200 nM towards USP1. The experimental process involved the reaction of 6-Chloro-4-methoxy-1H-pyrazolo[3,4-d]pyrimidine(cas: 98138-75-1).Recommanded Product: 6-Chloro-4-methoxy-1H-pyrazolo[3,4-d]pyrimidine

The Article related to pyrazolopyrimidines purine preparation usp1 inhibitor treatment cancer, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Recommanded Product: 6-Chloro-4-methoxy-1H-pyrazolo[3,4-d]pyrimidine

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On August 18, 2016, Gray, Nathanael S.; Hatcher, John; Choi, Hwan Geun published a patent.Name: 6-Chloro-4-methoxy-1H-pyrazolo[3,4-d]pyrimidine The title of the patent was LRRK2 inhibitors and methods of making and using the same. And the patent contained the following:

The invention relates to compounds of formula I, II, and III as LRRK2 inhibitors; their preparation and use in the treatment of neurodegenerative diseases, such as Parkinson’s disease. Compounds of formula I wherein Rx is NRARB, substituted piperidinylmethanone, substituted morpholinomethanone, etc.; RA and RB are independently (un)substituted C1-6 alkyl and COR7; R7 is (un)substituted C1-6 alkyl, (un)substituted C2-6 alkenyl, (un)substituted C2-6 alkynyl; X1, X2 and X3 are independently N, NH and derivatives, substituted C; Rn is H and (un)substituted C1-6 alkyl; each R1 is independently (un)substituted C1-6 alkyl, (un)substituted C1-6 alkoxy and halo; m = 0 – 3; R2 is H, alkoxy, halo, etc.; and pharmaceutically acceptable salts thereof, are claimed. Example compound IV was prepared by a multistep procedure (procedure given). The invention compounds were evaluated for their LRRK2 inhibitory activity (some data given). The experimental process involved the reaction of 6-Chloro-4-methoxy-1H-pyrazolo[3,4-d]pyrimidine(cas: 98138-75-1).Name: 6-Chloro-4-methoxy-1H-pyrazolo[3,4-d]pyrimidine

The Article related to pyrrolopyrimidine preparation lrrk2 inhibitor treatment neurodegenerative disease, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Name: 6-Chloro-4-methoxy-1H-pyrazolo[3,4-d]pyrimidine

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On June 25, 2020, Brenneman, Jehrod Burnett; Krall, Elsa Beyer; Schlabach, Michael; Wylie, Andrew Alistair published a patent.Recommanded Product: 6-Chloro-4-methoxy-1H-pyrazolo[3,4-d]pyrimidine The title of the patent was Preparation of substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors. And the patent contained the following:

The present disclosure provides compounds having formula I and the pharmaceutically acceptable salts and solvates thereof, wherein X1, X2 is independently N and CR2; R1 and R2 are independently H, halo, cyano, (un)substituted alkyl, etc.; R3 is (un)substituted Ph, pyridinyl, pyrazolyl, etc.; X11 and X12 is independently N and CH; R5′ is H, (un)substituted C1-6alkyl, (un)substituted C1-6alkoxy, etc.; R5 is (un)substituted C1-6alkyl, (un)substituted C2-6alkenyl, C1-6haloalkyl, etc.; R6 and R7 is independently H, halo, CN, (un)substituted alkenyl, etc. The present disclosure is also directed to the use of compounds of Formula I to inhibit a USP1 protein and to treat a disorder responsive to the inhibition of USP1 proteins and USP1 activity. Example compound II was prepared via a multistep procedure (procedure given). From the assay, it was determined that example compound II exhibited IC50 value of > 200 nM towards USP1. The experimental process involved the reaction of 6-Chloro-4-methoxy-1H-pyrazolo[3,4-d]pyrimidine(cas: 98138-75-1).Recommanded Product: 6-Chloro-4-methoxy-1H-pyrazolo[3,4-d]pyrimidine

The Article related to pyrazolopyrimidines purine preparation usp1 inhibitor treatment cancer, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Recommanded Product: 6-Chloro-4-methoxy-1H-pyrazolo[3,4-d]pyrimidine

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On April 1, 2021, Xie, Yinong; Babiss, Lee E. published a patent.SDS of cas: 98138-75-1 The title of the patent was Preparation of SHP2 inhibitors for treatment of cancer. And the patent contained the following:

Disclosed are compounds of formula I, useful as inhibitors of protein tyrosine phosphatase SHP2 for the treatment of cancer. Compounds of formula I [wherein X = S; Ring A = (un)substituted aryl having 6-10 carbons, (un)substituted 5- to 6-membered mono-cyclic heteroaryl, or (un)substituted bicyclic ring system having 5-10 ring carbons; RA and RB independently = H or C1-12 hydrocarbyl, or N(RA)(RB) optionally = substituted heterocyclic ring system] or pharmaceutically acceptable salts thereof, are claimed and exemplified. Thus, disubstituted 1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one II was prepared from a multistep synthesis (preparation given). Exemplified I were evaluated for inhibition of SHP2 from which II demonstrated an IC50 = ≤ 50 nM. The pharmaceutical compositions comprising compounds of Formula I, methods of synthesis of these compounds, methods of treatment for diseases associated with the aberrant activity of SHP2 such as cancer using these compounds or compositions containing these compounds are also disclosed. The experimental process involved the reaction of 6-Chloro-4-methoxy-1H-pyrazolo[3,4-d]pyrimidine(cas: 98138-75-1).SDS of cas: 98138-75-1

The Article related to dihydropyrazolopyrimidinone preparation shp2 inhibitor preparation inhibitor cancer, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.SDS of cas: 98138-75-1

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On September 26, 2019, Xie, Yinong; Babiss, Lee E. published a patent.Category: pyrazoles-derivatives The title of the patent was Preparation of SHP2 inhibitors and uses thereof. And the patent contained the following:

The invention relates to compounds of formula I and their preparation, useful as inhibitors of protein tyrosine phosphatase SHP2 in the treatment of diseases such as cancer. Compounds of formula I are claimed, in which ring A is (un)substituted aryl, heteroaryl, and bicyclic ring system; X is S, O, NRa, CHRa, S(O), SO2, C(O), or bond; Ra is H and C1-6 hydrocarbyl; ring B is (un)substituted mono-, bi-, tri-, or tetracyclic heterocyclic ring system containing heteroaryl and at least two ring N atoms; and pharmaceutically acceptable salts thereof. Example compound II was prepared via a multistep process with key step of coupling tert-Bu ((1-(5-chloro-4-cyano-1-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)-4-methylpiperidin-4-yl)methyl)carbamate with 2,3-dichlorophenylboronic acid followed by deprotection. Invention compounds were evaluated for their SHP2 inhibitory activity (data given). The experimental process involved the reaction of 6-Chloro-4-methoxy-1H-pyrazolo[3,4-d]pyrimidine(cas: 98138-75-1).Category: pyrazoles-derivatives

The Article related to shp2 inhibition treatment cancer, heteroaromatic preparation, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Category: pyrazoles-derivatives

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On August 29, 2019, Walters, W. Patrick; Lescarbeau, Andre; Kelley, Elizabeth H.; Shortsleeves, Kelley C.; Taylor, Alexander M.; Pierce, Levi Charles Thomas; Murcko, Mark Andrew; Giordanetto, Fabrizio; Greisman, Jack Benjamin; Maragakis, Paul; Bhat, Sathesh; Konze, Kyle; Dahlgren, Markus Kristofer; Therrien, Eric published a patent.Quality Control of 6-Chloro-4-methoxy-1H-pyrazolo[3,4-d]pyrimidine The title of the patent was Preparation of heterocyclic compounds as SHP2 phosphatase inhibitors. And the patent contained the following:

The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds and compositions of the disclosure. Example compound I•formate was prepared by cyclocondensation of tert-Bu (1-(5-amino-1,3,4-thiadiazol-2-yl)-3-methylpiperidin-3-yl)carbamate with 2,3-dichlorobenzaldehyde and 2-isocyano-2,4,4-trimethylpentane followed by deprotection. The invention compounds were evaluated for their SHP2 phosphatase inhibitory activity. From the assay, it was determined that compound I•formate exhibited IC50 value less than 5 μM. The experimental process involved the reaction of 6-Chloro-4-methoxy-1H-pyrazolo[3,4-d]pyrimidine(cas: 98138-75-1).Quality Control of 6-Chloro-4-methoxy-1H-pyrazolo[3,4-d]pyrimidine

The Article related to heterocycle preparation shp2 phosphatase inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Quality Control of 6-Chloro-4-methoxy-1H-pyrazolo[3,4-d]pyrimidine

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics